A Phase 3 interventional study of Beclomethasone Dipropionate/Formoterol Fumarate and Beclomethasone Dipropionate in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 91 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.
Among the 40 studies testing beclomethasone in Asthma, this one is the 2nd largest by enrollment, is one of 2 that started in 2022, is one of 20 in phase 3, and was the 39th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →
Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 22 · Phase 4 9
First in 1995; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,377 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 67 across the 40 interventional studies. Of the 35 that completed or were terminated, 14 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 40 have an industry lead sponsor. The 10 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
81 studies in Asthma by Chiesi Farmaceutici S.p.A.: 11 open now, 11 under way, 2 of them phase 3. Of 69 finished, 13 (19%) have results posted.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 3rd largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2022, is one of 24 in phase 3, and was the 62nd registered.
Chiesi Farmaceutici S.p.A.’s Asthma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing beclomethasone in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 81 in Asthma:
This tab as a report to print or save as PDF → With an account.
Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.
This was a phase III, multicenter, randomized, double-blind active controlled 2-arm parallel group to compare superiority of CHF 1535 pressurised metered dose inhaler (pMDI) compared with CHF 718 pMDI, in subjects with asthma on medium or high dose inhaled corticosteroids, with regard to change from baseline in forced expiratory volume in the first second (FEV1) Area under the Curve Calculated Between Time 0 and 12 Hours (AUC0-12h) at Week 12.
After screening, eligible subjects entered a 2-week run-in period using CHF 718 (BDP) pMDI 100µg, followed by a 12-week double-blind, treatment period. Screened subjects who were on a medium dose inhaled corticosteroid (ICS) or medium dose ICS-long-acting β2-adrenergic receptor agonists (LABA) prior to the study, received CHF 718 pMDI 100µg 2 inhalations twice daily (BID) i.e. total daily dose (TDD) 400µg) during the 2-week run in period. Screened subjects who were on a high dose ICS prior to the study received CHF 718 pMDI 100µg 4 inhalations BID (TDD 800µg) during the 2-week run in period.
Following the run-in period, eligible subjects were randomized to one of two study drug arms (using a 1:1 allocation ratio) for 12 weeks. A total of 6 clinic visits (V), (V0-V5) and a follow-up call (V6) were performed during the study.
During the study, daily symptoms, rescue medication use, and compliance with the study drug were recorded via a subject-specific electronic diary (eDiary). Concomitant medications and adverse events (AEs) were assessed and recorded throughout the study. Vital signs measurements, physical exam, 12-lead electrocardiogram (ECG), peak expiratory flow (PEF), and spirometry measurements, including serial spirometry were performed and recorded. Symptoms were assessed using disease specific questionnaires. Routine hematology, blood chemistry, and urine pregnancy testing were performed before enrolment and at the end of study.
CHF 1535 pMDI = 200/6 μg pressurised metered dose inhaler (fixed combination of extrafine beclomethasone dipropionate [BDP] plus formoterol fumarate [FF]).
CHF 718 pMDI = 100 μg pressurised metered dose inhaler (extrafine beclomethasone dipropionate [BDP]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Reversibility post-bronchodilator: Subjects with a positive reversibility to bronchodilator at screening, defined as an increase in FEV1 > 12% and > 200mL compared to baseline within 30 minutes after 4 inhalations of albuterol hydrofluoroalkane (HFA) pMDI 90µg/actuation.
Note for IC#5 and IC#6: In case the reversibility and/or quality threshold is not met at screening, the test can be performed once before randomization.
Female subjects:
a. Women of (WOCBP) fulfilling one of the following criteria: i. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective method from the signing of the informed consent form and until the follow-up contact or ii. WOCBP with non-fertile male partners (contraception is not required in this case).
b. Female subjects of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. or permanently sterile as per definitions given in Appendix 2). Tubal ligation or partial surgical interventions are not acceptable. If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CHF 1535 pMDI 800/24µg TDD
Drug: Beclomethasone Dipropionate/Formoterol Fumarate
CHF 718 pMDI 800µg TDD
Drug: Beclomethasone Dipropionate
Drug pages: Beclomethasone · Formoterol
Available in pressurized inhalation solution BDP/FF 200/6 µg
Also known as: BDP/FF
Available in pressurized inhalation solution BDP 100 µg
Also known as: BDP
1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12
The pre-dose FEV1 at baseline (i.e. pre-dose on Week 0 \[Visit 2\]) and the FEV1 AUC0-12h normalised by time at Week 12 (Visit 5) are presented by treatment group in the ITT population, as change from baseline. AUC0=12h Area under the curve calculated between time 0 and 12 hours
Time frame: Baseline (pre-dose on Week 0) and Week 12.
2_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 12
The peak FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the peak FEV1 within the first 3 hours post-dose at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second
Time frame: Baseline (pre-dose on Week 0) and Week 12.
3_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 0
The pre-dose FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the FEV1 AUC0-12h normalised by time at Week 0 (V2, post-dose) are presented by treatment group in the ITT population, as change from baseline.
Time frame: Baseline (pre-dose on Week 0) and Week 12.
4_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 0
The peak FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the peak FEV1 within the first 3 hours post-dose at Week 0 (V2, post-dose) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second
Time frame: Baseline (pre-dose on Week 0) and 3 h post dose on Week 0.
5_Change From Baseline in Trough FEV1 at Week 12
The trough FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]), the trough FEV1 at Week 12 (V5) and the change from baseline in trough FEV1 at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second
Time frame: Baseline (pre-dose on Week 0) and Week 12.
6_Change From Baseline in Pre-dose Morning FEV1 at Weeks 4, 8 and 12
The pre-dose MORNING FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the pre-dose morning FEV1 at Week 4 (V3), Week 8 (V4) and Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second
Time frame: Baseline (pre-dose on Week 0) and Week 4, Week 8, Week 12.
7_Proportion of Pre-dose Morning FEV1 Responders at Weeks 4, 8 and 12
The proportion of pre-dose MORNING FEV1 responders at Week 4 (V3), Week 8 (V4) and Week 12 (V5) are presented by treatment group in the ITT population. The proportion of subjects classified as pre-dose morning FEV1 responders (i.e. those subjects who had change from baseline in pre-dose morning FEV1 ≥100 mL). FEV1=Forced Expiratory Volume in the First Second
Time frame: Baseline (pre-dose on Week 0) and Week 4, Week 8, Week 12.
8_Proportion of Trough FEV1 Responders at Week 12
The proportion of trough FEV1 responders at Week 12 (V5) are presented by treatment group in the ITT population. The proportion of subjects classified as trough FEV1 responders (i.e. those subjects who had change from baseline in trough FEV1 ≥100 mL). FEV1=Forced Expiratory Volume in the First Second
Time frame: Baseline (pre-dose on Week 0) and Week 4, Week 8, Week 12.
9_Change From Baseline in Average Morning Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period
The average MORNING PEF at baseline (i.e. average morning "Best PEF" values during the run-in period, over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population), as change from baseline. PEF=Peak Expiratory Flow
Time frame: Baseline (Week 0) to Week 12.
10_Change From Baseline in Average Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period
The average EVENING PEF at baseline (i.e. average evening "Best PEF" values during the run-in period, see Section 9.7.1.4), over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline. PEF=Peak Expiratory Flow
Time frame: Baseline (Week 0) to Week 12.
11_Change From Baseline in ACQ-7 Score and ACQ-5 Score at Week 12
The ACQ-7 and ACQ-5 scores at baseline (i.e. pre-dose on Week 0 \[V2\]) and at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline; only patients who provided required data at baseline and at specified times are included in the calculation. Asthma control was evaluated during the treatment period (Week 0 to Week 12 \[V2-V5\])/end of treatment (ET) if applicable, using ACQ-7; first 6 items refer to symptoms and rescue use in the previous 7 days. The 7th item, filled in by the clinical staff, was the FEV1 (% predicted) recorded at 15 min pre-dose, measured at each visit during the treatment period. ACQ-5 has 5 items on adequacy of asthma control. ACQ-7: Assess asthma symptoms over last 7 days (night-time awakenings due to symptoms, morning symptoms, activity limitation, shortness of breath, wheezing), average daily rescue medication use, and current FEV1 percent predicted. Score scale: 0=totally controlled; 6=severely uncontrolled.
Time frame: Baseline (pre-dose on Week 0) and Week 12.
12_Change From Baseline in Percentage of Rescue Medication-free Days Over the 12-Week Treatment Period
The percentage of rescue medication-free days at baseline (i.e. percentage of days during the run-in period with no rescue medication), over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline.
Time frame: Baseline (pre-dose on Week 0) and Week 12.
13_Change From Baseline in Percentage of Asthma Symptom-free Days Over the 12-Week Treatment Period
The percentage of asthma symptom-free days at baseline (i.e. percentage of days during the run-in period with no asthma symptom, over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline.
Time frame: Baseline (pre-dose on Week 0) and Week 12.
Overall, 1377 participants were enrolled into the study; of these, 576 met eligibility criteria and were randomized to treatment.
| Milestone | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| Started | 287 | 289 |
| Completed | 276 | 267 |
| Not completed | 11 | 22 |
| Withdrew: Withdrawal by subject | 3 | 10 |
| Withdrew: Randomization error | 3 | 7 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Patient refused treatment | 1 | 0 |
| Withdrew: Patient could not travel to the study site | 1 | 0 |
| Withdrew: Technical issues with the masterscope | 0 | 3 |
| Withdrew: Patient moved to a different state | 0 | 1 |
The pre-dose FEV1 at baseline (i.e. pre-dose on Week 0 \[Visit 2\]) and the FEV1 AUC0-12h normalised by time at Week 12 (Visit 5) are presented by treatment group in the ITT population, as change from baseline. AUC0=12h Area under the curve calculated between time 0 and 12 hours
| liter | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 | 0.279 (0.248 to 0.309) | 0.174 (0.143 to 0.206) |
The peak FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the peak FEV1 within the first 3 hours post-dose at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second
| liter | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 2_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 12 | 0.419 (0.385 to 0.453) | 0.295 (0.260 to 0.330) |
The pre-dose FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the FEV1 AUC0-12h normalised by time at Week 0 (V2, post-dose) are presented by treatment group in the ITT population, as change from baseline.
| liter | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 3_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 0 | 0.250 (0.223 to 0.276) | 0.149 (0.122 to 0.175) |
The peak FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the peak FEV1 within the first 3 hours post-dose at Week 0 (V2, post-dose) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second
| liter | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 4_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 0 | 0.374 (0.345 to 0.404) | 0.262 (0.233 to 0.291) |
The trough FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]), the trough FEV1 at Week 12 (V5) and the change from baseline in trough FEV1 at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second
| liter | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 5_Change From Baseline in Trough FEV1 at Week 12 | 0.212 (0.179 to 0.244) | 0.143 (0.110 to 0.176) |
The pre-dose MORNING FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the pre-dose morning FEV1 at Week 4 (V3), Week 8 (V4) and Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second
| liter | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| Week 4 (V3) | 0.152 (0.121 to 0.182) | 0.107 (0.076 to 0.139) |
| Week 8 (V4) | 0.188 (0.154 to 0.222) | 0.147 (0.113 to 0.182) |
| Week 12 (V5) | 0.162 (0.132 to 0.193) | 0.120 (0.088 to 0.151) |
The proportion of pre-dose MORNING FEV1 responders at Week 4 (V3), Week 8 (V4) and Week 12 (V5) are presented by treatment group in the ITT population. The proportion of subjects classified as pre-dose morning FEV1 responders (i.e. those subjects who had change from baseline in pre-dose morning FEV1 ≥100 mL). FEV1=Forced Expiratory Volume in the First Second
| Participants | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| Week 4 (V3) | 154 | 130 |
| Week 8 (V4) | 162 | 141 |
| Week 12 (V5) | 162 | 125 |
The proportion of trough FEV1 responders at Week 12 (V5) are presented by treatment group in the ITT population. The proportion of subjects classified as trough FEV1 responders (i.e. those subjects who had change from baseline in trough FEV1 ≥100 mL). FEV1=Forced Expiratory Volume in the First Second
| Participants | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 8_Proportion of Trough FEV1 Responders at Week 12 | 181 | 136 |
The average MORNING PEF at baseline (i.e. average morning "Best PEF" values during the run-in period, over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population), as change from baseline. PEF=Peak Expiratory Flow
| liter/min | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 9_Change From Baseline in Average Morning Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period | 13.45 (9.58 to 17.32) | 4.67 (0.77 to 8.56) |
The average EVENING PEF at baseline (i.e. average evening "Best PEF" values during the run-in period, see Section 9.7.1.4), over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline. PEF=Peak Expiratory Flow
| liter/min | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 10_Change From Baseline in Average Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period | 10.27 (6.46 to 14.08) | 1.54 (-2.31 to 5.38) |
The ACQ-7 and ACQ-5 scores at baseline (i.e. pre-dose on Week 0 \[V2\]) and at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline; only patients who provided required data at baseline and at specified times are included in the calculation. Asthma control was evaluated during the treatment period (Week 0 to Week 12 \[V2-V5\])/end of treatment (ET) if applicable, using ACQ-7; first 6 items refer to symptoms and rescue use in the previous 7 days. The 7th item, filled in by the clinical staff, was the FEV1 (% predicted) recorded at 15 min pre-dose, measured at each visit during the treatment period. ACQ-5 has 5 items on adequacy of asthma control. ACQ-7: Assess asthma symptoms over last 7 days (night-time awakenings due to symptoms, morning symptoms, activity limitation, shortness of breath, wheezing), average daily rescue medication use, and current FEV1 percent predicted. Score scale: 0=totally controlled; 6=severely uncontrolled.
| score | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| ACQ-7 | -0.414 (-0.484 to -0.345) | -0.302 (-0.373 to -0.231) |
| ACQ-5 | -0.413 (-0.481 to -0.345) | -0.433 (-0.503 to -0.364) |
The percentage of rescue medication-free days at baseline (i.e. percentage of days during the run-in period with no rescue medication), over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline.
| percentage of days | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 12_Change From Baseline in Percentage of Rescue Medication-free Days Over the 12-Week Treatment Period | 17.923 (15.457 to 20.388) | 14.103 (11.617 to 16.589) |
The percentage of asthma symptom-free days at baseline (i.e. percentage of days during the run-in period with no asthma symptom, over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline.
| percentage of days | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| 13_Change From Baseline in Percentage of Asthma Symptom-free Days Over the 12-Week Treatment Period | 20.872 (17.908 to 23.836) | 17.092 (14.098 to 20.086) |
Collected over Adverse events (AE) were reported from the time of patient informed consent signature until study completion at week 12 or at study discontinuation.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CHF 1535 pMDI | 0/283 (0%) | 3/283 (1.1%) | 44/283 (15.5%) |
| CHF 718 pMDI | 0/280 (0%) | 0/280 (0%) | 53/280 (18.9%) |
| Event | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| OsteomyelitisInfections and infestations | 1/283 | 0/280 |
| Pneumonia influenzalInfections and infestations | 1/283 | 0/280 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/283 | 0/280 |
| Spinal cord injuryInjury, poisoning and procedural complications | 1/283 | 0/280 |
| Thoracic spinal stenosisMusculoskeletal and connective tissue disorders | 1/283 | 0/280 |
| Spinal cord compressionNervous system disorders | 1/283 | 0/280 |
| Event | CHF 1535 pMDI | CHF 718 pMDI |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 6/283 | 14/280 |
| Upper respiratory tract infectionInfections and infestations | 6/283 | 8/280 |
| NasopharyngitisInfections and infestations | 8/283 | 7/280 |
| Oral candidiasisInfections and infestations | 3/283 | 5/280 |
| HeadacheNervous system disorders | 3/283 | 5/280 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 5/283 | 0/280 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/283 | 1/280 |
| Back painMusculoskeletal and connective tissue disorders | 3/283 | 4/280 |
| COVID-19Infections and infestations | 4/283 | 3/280 |
| VomitingGastrointestinal disorders | 1/283 | 3/280 |
| Age, Categorical(Participants) | CHF 1535 pMDI | CHF 718 pMDI | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 231 | 237 | 468 |
| >=65 years | 52 | 43 | 95 |
| Age, Continuous(years) | CHF 1535 pMDI | CHF 718 pMDI | Total |
|---|---|---|---|
| Mean | 51.6 ± 14.1 | 50.3 ± 14.1 | 50.9 ± 14.1 |
| Sex: Female, Male(Participants) | CHF 1535 pMDI | CHF 718 pMDI | Total |
|---|---|---|---|
| Female | 210 | 202 | 412 |
| Male | 73 | 78 | 151 |
| Ethnicity (NIH/OMB)(Participants) | CHF 1535 pMDI | CHF 718 pMDI | Total |
|---|---|---|---|
| Hispanic or Latino | 154 | 165 | 319 |
| Not Hispanic or Latino | 129 | 113 | 242 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | CHF 1535 pMDI | CHF 718 pMDI | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 3 | 6 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 59 | 49 | 108 |
| White | 216 | 220 | 436 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Region of Enrollment(Participants) | CHF 1535 pMDI | CHF 718 pMDI | Total |
|---|---|---|---|
| United States | 283 | 280 | 563 |
| Body Mass Index (BMI)(kg/m^2) | CHF 1535 pMDI | CHF 718 pMDI | Total |
|---|---|---|---|
| Mean | 30.90 ± 6.93 | 30.86 ± 7.27 | 30.88 ± 7.09 |
| Time since first asthma diagnosis(months) | CHF 1535 pMDI | CHF 718 pMDI | Total |
|---|---|---|---|
| Mean | 474.6 ± 173.6 | 468.4 ± 180.9 | 471.5 ± 177.1 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website.
Ran from Aug 2022 to primary completion in Jun 2024, 21 months.
Results were first posted in Sep 2025, 1 year 2 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 21 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Beclomethasone · Formoterol